Welcome back to Plenary Session. This is Real Life Edition. We're back for the Malignant Book Club. I'm joined by Dr. Timothy Olivier.

Timothy, it's great to see you again. Great to see you and I. How are you today? Good, good. We've been hard at work, but we've made time on this busy day to do a little recording, a little recording. So where did we leave off, Timothy? Where do we leave off? So we covered so far the first section of the book,

the second section of the book that was a very important section about social forces.

And now we will be going into the weeds of how to interpret clinical evidence and how to

interpret clinical trials in cancer medicine.

My favorite part. Part three.

All right.

Part three.

So we start with chapter 9, which is called study design 201.

201, right. Because 101 was in the last book.

It's in the other book.

So basically this chapter is trying to underline some specificities about cancer clinical trial

as compared maybe with all the fields of medicine, right?

So you start, maybe I would just say you the titles and I know that this will trigger the discussion.

Okay.

Going nuts.

Going nuts. Going nuts.

Oh, yes.

I remember it well.

There was a study, I think, that came out of Dana Farber,

came out of Harvard Hospitals,

and it was entitled Going Nuts.

...